Restoring metabolic balance AND WEIGHT CONTROL

Harnessing precision-targeted drug formulations for the treatment and prevention of metabolic disorders such as obesity and related diseases

Our Approach

Metabolic disorders such as obesity or type 2 diabetes have emerged as a health and economic problem of global proportions, largely due to excessive consumption of calorie-rich highly refined food, sedentary lifestyles, and disruptions to circadian rhythms in modern work and living environments.

Aphaia is committed to offering patients therapeutic options that provide long-term benefits with minimal or no side effects by restoring the body’s natural physiology.

LEARN MORE

APH-012

LEAD DRUG CANDIDATE

We believe that our drug lead candidate, a proprietary oral glucose formulation, has the potential to revolutionize the treatment of metabolic disorders like obesity, type 2 diabetes, and associated diseases by addressing the underlying disease mechanism. It uniquely activates nutrient-sensing cells in the distal small intestine, restoring the endogenous release of the full spectrum of enteral hormones that control appetite, hunger, satiety, glucose metabolism, and other homeostatic functions.

LEARN MORE

Programs

PHASE 2 TRIALS IN OBESITY AND PREDIABETES

Aphaia’s lead drug candidate is being evaluated in two Phase 2 trials. The first proof-of-concept study in individuals with obesity evaluates its ability to change weight and other key parameters, hallmarking multiple metabolic diseases associated with obesity in a placebo-controlled design. The second trial is evaluating the drug’s ability to help prevent type 2 diabetes.

LEARN MORE

News

Aphaia Pharma Announces Positive Results from Phase 2 Trial Evaluating its Lead Drug Formulation

06/20/2024

Aphaia Pharma Announces Positive Results from Phase 2 Trial Evaluating its Lead Drug Formulation for Prediabetes Treatment

Primary endpoint met, showing that APHD-012 improves glucose tolerance in individuals with a pathological oral glucose tolerance test (OGTT) after 6 weeks of administration
The results provide proof-of-concept for clinical efficacy of Aphaia’s oral glucose formulation, designed to restore endogenous nutrient-sensing pathways in the gastrointestinal tract
The study confirms that APHD-012 is well tolerated, with no serious adverse events observed
Additional results from a Phase 2 trial evaluating Aphaia’s formulation in individuals with obesity are expected in H2 2024

Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial

06/13/2024

Aphaia Pharma Completes Enrollment in Arm 2 of Phase 2 Trial in Individuals with Obesity

Enrollment has been completed for the last four cohorts evaluating the contribution of circadian effects in weight loss treatment using Aphaia’s formulation
Topline data anticipated in Q3 and Q4 2024 for Arm 1 and Arm 2 of the trial, respectively

Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial

04/25/2024

Aphaia Pharma Provides Enrollment and Protocol Update for Phase 2 Trial in Individuals with Obesity

Enrollment has been completed for the first two cohorts evaluating a once-daily 12g dose of its oral glucose formulation (APHD-012)
The company is expanding its trial protocol to further explore the contribution of circadian effects in weight loss treatment with four additional cohorts
Topline data anticipated in Q3 and Q4 2024 for cohorts 1-2 and 3-6, respectively

All news